Data

health

More Data Tie Biologics to Fewer Colectomies in Ulcerative Colitis

Trends in colectomy rates over the past 2 decades reinforced data that biologics may reduce the need for colectomy in ulcerative colitis (UC), a researcher reported here.

A temporal trends analysis found the prevalence of colectomy decreased from 10.8% in 2000 to 2.1% in 2019, and this decline coincided with a linear increase in the prevalence of biologic medication utilization in UC from 0.5% in 2000 to 12.8% in 2019 (P<0.001), according to George Khoudari, MD, of the Cleveland Clinic and Case Western Reserve University.

“Although prior smaller data sets have suggested a decrease, there were no population-based studies to evaluate biologics on colectomy,” senior author Miguel Regueiro, MD, also of the Cleveland Clinic,” said in an interview. “We felt that evaluation of a real world large population-based database would be important.”

Data were extracted from the commercial database Explorys, a repository of electronic health records data from 26 major integrated U.S. healthcare systems from, he explained in a presentation at the American College of Gastroenterology virtual meeting.

Using Systematized Nomenclature of Medicine Clinical Terms, the investigators identified all UC patients older than age 18 to examine the prevalence of UC-related colectomy and biologics utilization. Biologics included anti-tumor necrosis factor, anti-integrin, and anti-interleukin-12/23 agents.

Of 61,592,650 patients in the database, 46,430 were diagnosed with UC from 2000 to 2019. Of these, 15,020 (10.2%) had colectomy and 10,050 (6.8%) were treated with biologics. After adjusting for other therapies such as mesalamine, corticosteroids, and thiopurines, biologics were inversely related to colectomy (P<0.001, respectively, while there was no inverse relationship between mesalamine and colectomy (P<0.001).

According to Regueiro, current data support the effectiveness of earlier use of biologics in the disease course. “Earlier use allows for better rates of healing and less inflammation equates to less likely need for colectomy.” But is it possible that biologics just delay the need for colectomy, especially in severe cases? “For patients hospitalized, which is not the population we studied, yes this is possible,” he said. “However there is some information coming out soon that complete remission of severe cases would also lead to less surgery, not just in the short term but the long term.”

Edward L. Barnes, MD, of the University of North Carolina at Chapel Hill, commented that the study was “an important next step in demonstrating what now appears to be a strong signal of a decreasing colectomy rate in recent years with the increased prevalence of biologic use among UC patients.”

While gastroenterologists have been optimistic that biologics would reduce colectomies, “this was initially only a hope,” said Barnes, who was not involved with the research. The current study as well as others support a genuine effect on colectomy rates.

And given that the new analysis included some of the newest UC treatments, such as anti-integrin and anti-interleukin-12/23 therapies, “there is hope that, with continued advancement of our therapeutic armamentarium, we will see a progression of this trend,” he said.

But Barnes added, “It is important

Read More
health

Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020

Basel, Switzerland, October 26, 2020

Basilea Pharmaceutica Ltd. (SIX: BSLN) today reported that data on the anti-angiogenic activity of the fibroblast growth factor receptor (FGFR) inhibitor derazantinib were presented at the 32nd EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, that took place as a virtual event on 24-25 October, 2020. In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2). The presented data from several preclinical models demonstrate that derazantinib has an anti-angiogenic effect, which may contribute to its overall anti-tumor activity in FGFR-driven cancers.

The prevention of new blood vessel formation (anti-angiogenesis) is an established approach in cancer therapy as it deprives the growing tumor from oxygen and nutrients. VEGFR2 is a primary target for anti-angiogenic agents in the treatment of cancers.

Dr. Laurenz Kellenberger, Chief Scientific Officer, said: “Our development strategy for derazantinib is focused on strengthening the evidence for its differentiation versus other FGFR inhibitors. The preclinical data on derazantinib’s anti-angiogenic activity presented at the conference show that it may provide additional activity on top of its established primary anti-tumor effects in FGFR-positive solid tumors. Based on its unique kinase inhibition profile, we are exploring derazantinib’s potential for enhanced activity alone and in combination with other anti-cancer agents such as the anti-VEGFR2 antibody ramucirumab, or the PD-L1 immune checkpoint inhibitor atezolizumab within our ongoing clinical program FIDES.“

The following e-poster was presented at the EORTC-NCI-AACR Virtual Symposium 2020:

Presentation #

Authors/title

101

P. McSheehy, J. Boult, S. Robinson, F. Bachmann, M. El-Shemerly, L. Kellenberger, H. Lane

Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in preclinical models

For further information, please visit https://event.eortc.org/ena2020

About derazantinib

Derazantinib is an investigational orally administered small-molecule FGFR inhibitor with strong activity against FGFR1, 2, and 3.1 FGFR kinases are key drivers of cell proliferation, differentiation and migration. FGFR genetic aberrations, e.g. gene fusions, mutations or amplifications, have been identified as potentially important therapeutic targets for various cancers, including intrahepatic cholangiocarcinoma (iCCA), urothelial, breast, gastric and lung cancers.2 In these cancers, FGFR genetic aberrations are found in a range of 5% to 30%.3
Derazantinib also inhibits the colony-stimulating-factor-1-receptor (CSF1R) kinase.1, 4 CSF1R-mediated signaling is important for the maintenance of tumor-promoting macrophages and therefore has been identified as a potential target for anti-cancer drugs.5 Preclinical data has shown that tumor macrophage depletion through CSF1R blockade renders tumors more responsive to T-cell checkpoint immunotherapy, including approaches targeting PD-1/PD-L1.67
Derazantinib has demonstrated antitumor activity and a manageable safety profile in a previous biomarker-driven phase 1/2 study in iCCA patients,8 and has received U.S. and EU orphan drug designation for iCCA. Basilea is currently conducting three clinical studies with derazantinib. The first study, FIDES-01, is a registrational phase 2 study in patients with inoperable or advanced iCCA. It comprises one cohort of patients with FGFR2 gene fusions and another cohort of patients with mutations or amplifications.

Read More
health

Active COVID-19 Cases In New Hampshire The Most Since June: Data

CONCORD, NH — Another 92 New Hampshire residents tested positive for COVID-19 after more than 7,000 polymerase chain reaction specimens were collected on Saturday.

Prior test counts were upgraded and nearly 900 tests are pending bringing the daily positivity rate to 0.8 percent. Most of the positive tests were found via PCR testing with a little less than a third by antigen tests.

There are currently 1,032 active COVID-19 cases diagnosed in New Hampshire — the most since mid-June.

Hospitalizations in New Hampshire are still low — 23 and only 7 percent of cases required more care since the pandemic started in early March.

Of the new cases, 12 were children, cases were split nearly evenly between women and men, and some cases are still under investigation by the state, including determining the residency of five new cases. Of the rest, 23 reside in Rockingham County, 20 live in Hillsborough County outside of Manchester and Nashua, 10 live in Merrimack, and nine live in Nashua. The increase in cases today as well as extensive numbers during the past few weeks in Rockingham County, including outbreaks at Portsmouth restaurants, have pushed the county into the substantial community transmission category on the school data dashboard.

“Five of the new cases had no identified risk factors,” the State Joint Information Center said. “Community-based transmission continues to occur in the State and has been identified in all counties. Of those with complete risk information, most of the cases have either had close contact with a person with a confirmed COVID-19 diagnosis, are associated with an outbreak setting, or have recently traveled.”

Accumulatively, 10,328 have been diagnosed with coronavirus while 8,823 have recovered from the virus — about 85 percent. The state said 331,561 residents have been tested or 22.2 percent via 579,186 PCR tests. Another 32,000 people have been tested with antibody tests.

Approximately 4,450 people are under public health monitoring in New Hampshire.

In K-12 schools in New Hampshire, there are 66 active cases after the state reported a number of new school cases since Friday.

Heron Pond Elementary School in Milford has two active cases; Manchester Central High School has its first case; Milford High School has two new active cases; North Hampton School has a second new active case; the Penacook Elementary School in Concord has a new case; the Riddle Brook Elementary School has its four active case; the South Range Elementary School in Derry has its second active case; and Saint Joseph Regional School in Keene and St. Mary Academy in Dover both have their first cases.

There are also five active cases at the University of New Hampshire School of Law in Concord while there are 18 active cases at UNH in Durham. The university has 187 cases. Plymouth State College and Keene State College have four active cases each while Colby-Sawyer College, Dartmouth College, Franklin Pierce University, and White Mountains Community College have a single case each. Rivier University has five active cases while New England College

Read More
health

Alabama adds 3,852 COVID cases after influx of backlogged data dating back to June

Alabama added more than 3,800 COVID cases yesterday after a huge influx of backlogged data dating back to June.

The Alabama Department of Public Health showed a total of 180,916 coronavirus cases in the state, up 3,852 from the day before. Of that total, 973 were confirmed cases and 2,879 were probable. Of that 2,879, the 2,565 were antigen tests from a facility in Mobile that dated back to the summer.

The cases “will be classified as probable COVID-19 cases reported on 10/22/20 even though the tests were performed during June through Oct. 18. All laboratories are required by law to report all results (including positive and negative results) for (COVID-19) to ADPH,” the agency said in an announcement.

“Delays in reporting by required reporters is not within control of ADPH. Processing the backlog will not impact the ADPH COVID-19 Risk Indicator Dashboard,” ADPH added.

The state added 16 deaths to bring its total to 2,859.

ADPH reports 864 patients are currently hospitalized due to coronavirus.

Here are the latest county-by-county numbers from the Alabama Department of Public Health. The numbers include both confirmed and probable cases with the overnight increases shown in parenthesis:

Autauga – 2030 (+7)

Baldwin – 6615 (+140)

Barbour – 1012 (+15)

Bibb – 825 (+14)

Blount – 1911 (+13)

Bullock – 639 (+2)

Butler – 1002 (+1)

Calhoun – 4224 (+35)

Chambers – 1343 (+7)

Cherokee – 731 (+5)

Chilton – 1858 (+17)

Choctaw – 390 (+2)

Clarke – 1336 (+36)

Clay – 736 (+7)

Cleburne – 551 (+8)

Coffee – 1732 (+15)

Colbert – 1987 (+20)

Conecuh – 560 (+3)

Coosa – 203 (+1)

Covington – 1714 (+15)

Crenshaw – 603 (+1)

Cullman – 2399 (+42)

Dale – 1665 (+11)

Dallas – 1863 (+1)

DeKalb – 3360 (+58)

Elmore – 3173 (+24)

Escambia – 1722 (+3)

Etowah – 4214 (+27)

Fayette – 569 (+8)

Franklin – 2032 (+11)

Geneva – 861 (+9)

Greene – 342

Hale – 758 (+9)

Henry – 643 (+4)

Houston – 3717 (+25)

Jackson – 2125 (+25)

Jefferson – 22987 (+137)

Lamar – 474 (+8)

Lauderdale – 2180 (+32)

Lawrence – 837 (+16)

Lee – 6517 (+21)

Limestone – 2797 (+32)

Lowndes – 704 (+1)

Macon – 530 (+1)

Madison – 9228 (+78)

Marengo – 1002 (+10)

Marion – 1071 (+9)

Marshall – 4372 (+42)

Mobile – 16,788 (+2,320)

Monroe – 645 (+5)

Montgomery – 9978 (+103)

Morgan – 4071 (+35)

Perry – 585 (+2)

Pickens – 836 (+12)

Pike – 1327 (+4)

Randolph – 820 (+8)

Russell – 1928 (+5)

St. Clair – 2891 (+20)

Shelby – 7274 (+70)

Sumter – 472 (+2)

Talladega – 2636 (+25)

Tallapoosa – 1313 (+8)

Tuscaloosa – 10,235 (+87)

Walker – 2755 (+33)

Washington – 734 (+100)

Wilcox – 564 (+2)

Winston – 919 (+6)

Source Article

Read More
health

Hospitalization data flawed in Missouri, perhaps elsewhere

O’FALLON, Mo. (AP) — With the number of coronavirus patients requiring hospitalization rising at alarming levels, Missouri and perhaps a handful of other states are unable to post accurate data on COVID-19 dashboards because of a flaw in the federal reporting system.

Since Tuesday, the Missouri Department of Health and Senior Service’s coronavirus dashboard has posted a message that the total number of patients hospitalized for COVID-19 has been underreported since Oct. 17. The note blamed “challenges entering data” to the portal used by the U.S. Department of Health and Human Services for collecting daily hospitalizations around the country.

It wasn’t immediately clear on Friday how many states are impacted since some states rely on their own hospitalization counts, not HHS data collection. HHS did not immediately respond to phone and email messages seeking comment.

But The COVID Tracking Project said in a blog post that it has “identified five other states with anomalies in their hospitalization figures” that could be tied to the HHS reporting problem.

The project noted that the number of reported intensive care unit patients in Kansas had decreased from 80 to one without explanation. It said Wisconsin’s hospitalization figures stayed unexpectedly flat while other indicators worsened. And it said Georgia, Alabama, and Florida reported only partial updates to hospitalization data.

Kansas Department of Health and Environment spokeswoman Kristi Zears confirmed that the “ICU admission data displayed on our website is not current. We did post a notice on our dashboard today to convey that as well. We anticipate the issue will be resolved for our Monday update.”

A spokeswoman for the Wisconsin Department of Health Services said the state’s reporting was accurate, with the number of hospitalizations holding steady for one day, Wednesday, before rising again on Thursday. A Georgia Department of Public Health spokeswoman said the department was unaware of any problems with its data. Health department representatives in the other states mentioned in the blog didn’t immediately respond to Associated Press requests for comment.

In Missouri, the loss of accurate hospitalization data comes as confirmed cases continue to rise. On Friday, Missouri reported 1,811 new cases of COVID-19, and 31 additional deaths. Since the onset of the pandemic, Missouri has cited 164,534 confirmed cases and 2,688 deaths.

Missouri also has seen a steady rise in COVID-19 hospitalizations since September. The state reached record levels of hospitalizations several times earlier this month, with every region except St. Louis seeing record or near-record spikes. Since July 7, when 375 people were hospitalized statewide, that number has nearly quadrupled to a peak of 1,465 hospitalizations on Oct. 14.

The problem is especially worrisome in rural areas, where some hospitals are nearing capacity. Others are using makeshift buildings or previously vacant hospital wings to serve overflow patients. Some are simply redirecting people to larger hospitals.

State health department spokeswoman Lisa Cox said the federal hospital reporting system, known as TeleTracking, went down. “As a result they experienced underreporting – so hospitalization numbers were lower than they should’ve

Read More
medicine

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases

— GFB-887, a first-in-class highly potent and selective inhibitor of the TRPC5-Rac1 pathway, was well-tolerated in single ascending doses —

— GFB-887 induced dose-dependent reductions in urinary Rac1, demonstrating target engagement —

— TRPC5-Rac1 pathway overactivation is key cause of disease in substantial portion of patients with focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN) —

— Phase 2 clinical study of GFB-887 (TRACTION-2) underway; initial data expected in the first quarter of 2021 —

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced for the first time results from its Phase 1 clinical trial evaluating GFB-887, a first-in-class highly potent and selective inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), in healthy volunteers. The data are being presented today at the virtual American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting.

Goldfinch Bio is developing GFB-887 as a precision medicine for patients with kidney diseases characterized by overactivation of the TRPC5-Rac1 pathway, including focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Overactivation of the TRPC5-Rac1 pathway leads to injury of podocytes, which are cells lining the kidney that, in their healthy state, prevent essential protein loss (proteinuria). Injury to podocytes causes podocyte loss, proteinuria and, eventually, kidney failure. TRPC5-Rac1 pathway overactivation is the key cause of disease in a substantial portion of FSGS and DN patients, and there are currently no approved drugs that specifically target the TRPC5-Rac1 pathway in these diseases.

“We are excited to share these first-in-human data, which demonstrate that GFB-887 is well-tolerated and suggest a dose-dependent reduction in urinary Rac1, confirming GFB-887 target engagement in the podocyte,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. “Suppressing the TRPC5-Rac1 pathway has the potential to deliver clinically meaningful benefit to patients by reducing proteinuria and, as a result, preserving native kidney function. Supported by the Phase 1 data, we are now underway with our Phase 2 TRACTION-2 study of GFB-887 in FSGS and DN, as we continue to advance our mission of protecting patients from the inevitability of dialysis and kidney transplant by delivering precision medicines for subsets of kidney disease.”

Data from the Phase 1 Clinical Trial

The primary objective of the randomized, double-blinded, placebo-controlled trial was to assess the safety, tolerability, pharmacokinetic (PK) profile and pharmacodynamics (PD) of GFB-887 in healthy volunteers. A key exploratory objective was to characterize changes in urinary Rac1. Urinary Rac1 concentration may predict therapeutic response to TRPC5 inhibition.

The study enrolled 70 subjects, who were randomized four to one to receive GFB-887 at seven dose levels (ranging from 5 mg to 900 mg) or placebo.

Primary Objective: Safety, Tolerability and PK Data

GFB-887 was observed to be well-tolerated at all doses. There were no dose-limiting toxicities, severe adverse events (AEs) or abnormalities in laboratory or clinical assessments. In total, 38 percent of subjects who received GFB-887 reported AEs, compared to 21 percent of subjects treated with placebo. GFB-887-treated subjects

Read More
health

Louisiana coronavirus: 696 cases, 21 more deaths reported Friday; see latest data | Coronavirus

The Louisiana Department of Health reported 696 more coronavirus cases and 21 more deaths in its noon update Friday.

The number of hospitalizations increased by 22, and the number of patients in need of ventilators increased by one.

Here are a few key statewide statistics as of Friday:

— Total cases: 178,870

— Total deaths: 5,614

— Currently hospitalized: 620

— Currently on ventilators: 65

— Presumed recovered: 165,282 as of Oct. 19 (updated weekly)

— Probable cases: 3,733 as of Oct. 21 (updated weekly)

Note: The Advocate and The Times-Picayune staff calculates daily case count increases based on the difference between today’s total and yesterday’s total of confirmed coronavirus cases. The Louisiana Department of Health releases a daily case count on Twitter based on the deletion of duplicate cases. That case count can be different than the one listed here.

You can view more graphs and charts breaking down the data by clicking here.

Louisiana began reopening for Phase 1 on May 15-16 then moved to Phase 2 on June 5. Louisiana Gov. John Bel Edwards extended Louisiana’s Phase 2 restrictions twice in August before moving the state to Phase 3 on Sept. 11.

This is a developing story. More details and analysis to come.

Source Article

Read More
health

Real-time pandemic data from Carnegie Mellon’s CovidCast shows why you should wear a mask

For all 50 states plus D.C., this chart plots the percentage of state residents who say they wear a mask in public all or most of the time (on the horizontal axis) and the percentage who say they know someone in their community with virus symptoms (on the vertical axis).

Take Wyoming and South Dakota, for instance, in the upper left-hand corner of the chart. Roughly 60 to 70 percent of state residents report frequent mask use, as shown on the bottom axis, which puts them at the bottom for mask rates. They also have some of the highest levels of observed covid-19 symptoms, approaching 40 and 50 percent.

Now, note what happens as you move across the chart. States farther to the right have higher rates of mask use. And as mask use increases, the frequency of observed covid-19 symptoms decreases: More masks, less covid-19.

Let’s pause a minute to talk about where exactly this data comes from. Ideally you would want it to be from something like a random-digit-dial survey, the type typically used in public opinion polling, which with enough participants would produce a sample of each state that’s representative of its population and demographics. But the cost of running one such survey for all 50 states plus D.C. would be enormously prohibitive — to say nothing of doing so on a daily basis, which is necessary to produce the kind of real-time data of interest to epidemiologists.

“If Facebook’s users are different from the U.S. population generally in a way that the survey weighting process doesn’t account for, then our estimates could be biased,” cautioned Alex Reinhart, a Carnegie Mellon professor of statistics and data science who works on CovidCast and wrote a book on statistical methods. “But if that bias doesn’t change much over time, then we can still use the survey to detect trends and changes.”

He also cautioned that the old saw of “correlation doesn’t equal causation” applies here as well.

“There could be other explanations for the correlation,” he said. “For example, states that had worse outbreaks earlier in the pandemic both have higher mask usage now and more immunity.”

And, he added, “if people say they’re not wearing masks, they may not be taking other protective measures either. So perhaps what we see is a combination of mask usage, other social distancing behaviors and perhaps other factors we haven’t measured.”

Nevertheless, the chart is particularly useful in the context of all the other high-quality evidence showing that masks reduce the transmission of the coronavirus and other respiratory diseases. There’s good reason to suspect, in other words, that rates of mask use are driving at least part of the relationship seen in the chart above, even if the data can’t prove that definitively.

For people living in states that are driving the latest spike in coronavirus cases, the takeaway is clear: Wear a mask when you go out in public.

Source Article

Read More
health

Experts Tell F.D.A. It Should Gather More Safety Data on Covid-19 Vaccines

Vaccine experts peppered officials at the Food and Drug Administration with a range of questions on Thursday about its guidelines for approving a coronavirus vaccine, pushing the agency on whether it should wait longer to collect more safety data and whether an emergency approval could jeopardize the outcome of the broader clinical trials.

The stakes, the experts said, could not be higher. Even as a vaccine is seen as crucial to ending the pandemic, opinion polls have shown that Americans are increasingly skeptical about the products and worry that the vetting process is being rushed.

“In this particular case, public trust equals success,” said Sheldon Toubman, the consumer representative on the advisory group. “Lack of trust means no success.”

The meeting, which lasted all day and was broadcast on YouTube, also included a presentation by a nonprofit group that interviewed people about their views about a coronavirus vaccine. Several people of color expressed concern about whether the vaccine had been studied in people who are Black, Latino or Native American.

Others said their skepticism had historical roots dating to the Tuskegee Syphilis Study, in which government scientists lied to Black men and allowed them to go untreated for syphilis. “I firmly believe that this is another Tuskegee experiment,” one participant said.

The expert panel was not asked to evaluate a specific vaccine — none of the companies developing one so far have results from large clinical trials — but rather to weigh in on how the F.D.A. should vet the candidates. The agency has said that it will ask the panel for its opinion before approving any coronavirus vaccine for emergency use. The agency typically, but not always, follows the advice of its outside experts.

Four companies are conducting late-stage clinical trials in the United States, and some have estimated they will have preliminary data that may allow them to apply for emergency authorization in certain high-risk groups by the end of November. One of the companies, Moderna, said on Thursday that it had fully enrolled its trial of 30,000 participants, the first company to do so.

Several of the experts said that they believed the agency should ask the companies to wait for more safety data. They said the agency’s current guidelines, which require two months of safety data after a volunteer has received the last dose of a vaccine, were not good enough. Collecting longer-term data would allow them to evaluate potential risks, such as whether immunity to the virus wanes after a few months, or whether rare side effects emerge.

The experts were also asked to give their opinions about what should happen to the clinical trials if the F.D.A. were to approve a vaccine for emergency use based on promising early data. Pfizer has said that if a vaccine is approved for emergency use, the company will be ethically obligated to offer the vaccine to people in the trial who received a placebo instead of the actual vaccine. But this would “unblind” the trial by revealing

Read More
health

Former Windows chief Terry Myerson is building a health care data startup called Truveta



Terry Myerson smiling for the camera


© Provided by Geekwire
Terry Myerson

A Seattle-area startup called Truveta made its existence known for the first time on Thursday, describing an ambitious vision to use data to save lives through new innovations in patient care and therapies.

The company’s CEO is Terry Myerson, a former Microsoft executive who led the company’s Windows and Devices Group before departing in 2018 after a 21-year career at the tech giant.

Truveta has already hired nearly 20 people, including some of Myerson’s former colleagues from the Redmond company, and it has enough open positions to double the size of the team.

Loading...

Load Error

The company joins a growing number of startups and tech giants seeking to use data to transform health care. It also follows a trend of tech industry veterans seeking to apply their technical expertise to big problems in health, often learning that the challenges are even bigger than they imagined.

“As the COVID-19 pandemic continues to impact our world, loved ones, and daily lives, the opportunity to apply data in the development of breakthrough health solutions has never been clearer,” Myerson wrote in a post introducing the company on Thursday morning. “We will pursue this vision in close collaboration with health systems, life science researchers, physicians, and others in the health community.”

He promised a strong focus on privacy: “We know health data is unlike other data. It is the very definition of personal. While we embark on our pursuit to generate knowledge and insights to improve diagnoses and treatments, we know we must do so with the utmost caution to protect the privacy of the people we ultimately seek to serve: patients.”

The company declined to go into detail about its plans, origins, ownership, or funding, but public records offer some hints about its collaborations.

A trademark filing links the startup’s name to Providence Health & Services, the large health care system based in Washington state, which has been spinning out a series of health care startups in recent years. Providence also runs a $300 million venture capital fund that invests in early-to-mid-stage healthcare companies.

Wasif Rasheed, the Providence senior vice president and head of corporate development, is listed as one of the governing members of Truveta in Washington state corporations records. Truveta’s address in its state filings is the same as Providence’s office in Renton, Wash.

Responding to an inquiry from GeekWire, a Providence spokesperson acknowledged that the health system is working with Truveta, without providing specifics on their relationship.

“At Providence, we are focused on accelerating transformation across health care, driving quality, affordability and a better experience for health care organizations, providers and patients,” the spokesperson said via email. “Truveta’s vision is to contribute meaningfully to breakthroughs in research, treatments, and therapies. We are in the early stages of collaborating and will share more information in the near future.”

Others listed as governing members of Truveta include Dr. Bobbie Byrne, chief information officer at AdvocateAuroraHealth, based in Illinois and Wisconsin; Marcus Shipley, senior vice president and

Read More